

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

Dennis McKenna and Jordi Riba

Abstract New World indigenous peoples are noted for their sophisticated use of psychedelic plants in shamanic and ethnomedical practices. The use of psychedelic plant preparations among New World tribes is far more prevalent than in the Old World. Yet, although these preparations are botanically diverse, almost all are chemically similar in that their active principles are tryptamine derivatives, either DMT or related constituents. Part 1 of this paper provides an ethnopharmacological overview of the major tryptamine-containing New World hallucinogens. Part 2 focuses on ayahuasca and its effects on the human brain. Using complementary neurophysiological and neuroimaging techniques, we have identified brain areas involved in the cognitive effects induced by this complex botanical preparation. Initial SPECT data showed that ayahuasca modulated activity in higher order association areas of the brain. Increased blood perfusion was observed mainly in anterior brain regions encompassing the frontomedial and anterior cingulate cortices of the frontal lobes, and in the medial regions of the temporal lobes. On the other hand, applying spectral analysis and source location techniques to cortical electrical signals, we found changes in neuronal activity that predominated in more posterior sensory-selective areas of the brain. Now, using functional connectivity analysis of brain oscillations we have been able to reconcile these seemingly contradictory findings. By measuring transfer entropy, a metric based on information theory, we have shown that ayahuasca temporarily modifies the ordinary

D. McKenna

Director of Ethnopharmacology, Heffter Research Institute,

Santa Fe, NM, USA

e-mail: mcken031@umn.edu

J. Riba (✉)

Human Neuropsychopharmacology Research Group, Sant Pau Institute

of Biomedical Research (IIB-Sant Pau), C/Sant Antoni Maria Claret, 167,

08025 Barcelona, Spain

e-mail: jriba@santpau.cat

J. Riba

Department of Pharmacology and Therapeutics, Universitat Autònoma

de Barcelona (UAB), Barcelona, Spain

flow of information within the brain. We propose a model in which ayahuasca reduces top-down constraints and facilitates bottom-up information transfer. By simultaneously enhancing endogenous cortical excitability and reducing higher-order cognitive control, ayahuasca temporarily disrupts neural hierarchies allowing inner exploration and a new outlook on reality.

Keywords Tryptamine derivatives • Tryptamine hallucinogen • Hallucinogenic • New World • Shamanism • Botany • Chemistry • Ethnopharmacology

Contents

1	Botany, Chemistry, and Ethnopharmacology of New World Tryptamine Hallucinogens	284
1.1	Introduction.....	284
1.2	Chemistry, Botany, and Pharmacology.....	286
1.3	Survey of New World Tryptamine Hallucinogens.....	289
2	The Neuroscience of Ayahuasca.....	298
2.1	The Nuclear Medicine Approach.....	298
2.2	Spectral Analysis of Brain Electrical Activity.....	299
2.3	Structural Brain Modifications in Long-Term Users.....	301
2.4	Functional Connectivity of Brain Oscillations.....	303
2.5	A Model of Psychedelic Drug Effectson the Human Brain.....	305
2.6	Concluding Remarks	307
	References	307

1 Botany, Chemistry, and Ethnopharmacology of New World Tryptamine Hallucinogens

1.1 Introduction

The indigenous cultures of the New World are infinitely more sophisticated than their Old World counterparts in their knowledge and utilization of vision-producing, or hallucinogenic, plants. Fewer than 100 genera have been identified as “major hallucinogens,” meaning that they form an important component of ethnomedical and ritual practices in one or more indigenous societies; fully sixty genera are used by New World aboriginal peoples, while only a dozen or so are utilized in Old World indigenous cultures (Schultes 1970a, b). This curious asymmetry in the ethnographic utilization of visionary plants has never been satisfactorily explained. One difficulty is that documentation of the antiquity of hallucinogenic plant use is drawn from sources that are much more recent than the actual practices, and archeological evidence, in the form of plant remains or artifacts used in drug rites, is rare to nonexistent. *Amanita muscaria*, the Fly Agaric mushroom, is at the root of shamanism, which has its origins among the Finno-Ugric peoples who are thought to have settled

west of the Urals sometime after the end of the last Ice Age, between 8000 and 4200 BP. Linguistic analysis of Northern European languages indicates that the Uralic languages split into two branches about 4000 BP. Both of these branches contain similar words for “inebriation,” and in some of these languages, the root “pang” signifies both intoxication and the *Amanita muscaria* mushroom. This evidence suggests, but does not prove, that *Amanita muscaria* was known to be an intoxicant prior to the linguistic split (Wasson 1968). There is evidence that earlier settlements existed in the region before the end of the last Ice Age and thus are more than 10,000 years old. There is no information on whether these cultures also used *Amanita*, and whether they had any cultural relation to the Finno-Ugric cultures. The dates for the ingression of Siberian or northern Asian people into the Americas are uncertain and cover a wide range. Discovery of human-worked mammoth bone artifacts in Bluefish Cave in the Canadian Yukon has been dated to 25,000–40,000 BP; this date currently stands as the best documented evidence of the earliest human habitation in the New World (Cinq-Mars and Morlan 1999).

It is likely, but impossible to prove, that the earliest immigrants into the North American continent may have brought with them both a tradition and a technology of psychoactive plant utilization; as these populations gradually expanded southward into the fecund rainforest ecosystems of Central and South America, they would have encountered an increasingly unfamiliar and biodiverse flora. Their penetration into these novel ecosystems, coupled with innate human curiosity, probably vastly expanded their access to plants utilized as food, as well as to floras rich in biodynamic plant species that included a greater variety of hallucinogens. Whether such migratory peoples already practiced shamanic traditions aided by divine intoxication with them, or discovered a rich new pallet of psychoactive species that fostered the development of purely New World practices, will probably never be known. What does seem certain, however, is that the innate human drive to access shamanic dimensions reached its fullest symbiotic expression in the tryptamine-saturated tropical rain forests of the New World. The legacy of that Paleolithic application of human ingenuity and curiosity to empirical psychopharmacological experimentation in an ecology of incredible chemical diversity persists to the present day in the many traditions involving the use of psychoactive plants that can still be found among New World aboriginal peoples.

While the ingenuity displayed by the New World Indians in discovering and utilizing psychoactive plants drawn from numerous families and genera is remarkable, perhaps equally remarkable is the fact that in most instances the active principles responsible for their psychoactive properties can be traced to chemical compounds known as tryptamines. With only three exceptions—the peyote cactus of North America and Mexico, the morning glories (*ololiuqui*) of Central America, and the columnar San Pedro cacti of the Andes—almost all of the “major” New World hallucinogens are derived from plants containing tryptamine derivatives. This section of this chapter presents an ethnopharmacologic overview of tryptamine-containing New World hallucinogens, including their botanical sources, chemistry, and pharmacology, and their geographic and ethnographic distribution.

1.2 Chemistry, Botany, and Pharmacology

Tryptamine derivatives are simple indole alkaloids, derived biosynthetically from tryptophan, an essential amino acid that is universally distributed in all plants and animals (although many animals, including man, cannot synthesize tryptophan *de novo* and must obtain it from dietary sources, which is why it is considered an “essential” amino acid). Decarboxylation of tryptophan by aromatic amino acid decarboxylase, an enzyme fundamental to basic metabolic processes in plants and animals, yields tryptamine, the structurally simplest of the tryptamine derivatives (Fig. 1).

Hydroxylation of tryptamine at position 5 on the indole ring yields 5-hydroxytryptamine (5-HT), also known as serotonin. Serotonin is widely distributed in plants where it functions as a defensive, irritant compound, e.g., in the leaves of nettles (*Urtica* spp.). Serotonin is also a major central nervous system neurotransmitter, and most hallucinogenic drugs are thought to be agonists at 5-HT_{2A} receptors, one of about fourteen subtypes of serotonin receptors. Tryptamine itself is not psychoactive, nor is serotonin, apart from a mild sedative effect; similar sedating and tranquilizing effects have been ascribed to tryptophan itself, undoubtedly because it is a precursor to serotonin in the central nervous system. A trivial chemical modification of tryptamine, viz. the addition of two




Fig. 1 Biosynthesis of simple tryptamines and β -carbolines from tryptophan

methyl (CH₃) groups to the side chain nitrogen, yields the simplest of the hallucinogenic tryptamines, *N,N*-dimethyltryptamine (DMT). A closely related compound, bufotenine (5-hydroxy-*N,N*-dimethyltryptamine, 5-OH-DMT), can be derived from serotonin by a similar methylation reaction; bufotenine is so named because it is found in the skins of certain toads belonging to the genus *Bufo*. There is some controversy as to whether bufotenine is hallucinogenic or otherwise psychoactive, as it putatively does not cross the blood–brain barrier and purportedly produces only peripheral autonomic effects. However, careful self-bioassay experiments by Ott (2001) have established definitively that bufotenine is indeed psychoactive, although its activity is critically affected by dose and route of administration, as well as the chemical form of the alkaloid (salt or free base). Two further minor modifications of bufotenine can result in potent hallucinogens. *O*-Methylation of the hydroxy group of bufotenine yields 5-methoxy-*N,N*-dimethyltryptamine (5-MeO-DMT), a compound similar to DMT in that it is a short-acting hallucinogen, but that is approximately 10 times more potent, on a per weight basis. The 4-hydroxy regioisomer of bufotenine is psilocin (4-hydroxy-DMT), which is the active principle of hallucinogenic “magic” mushrooms, first described from Mexico. This compound is derived from psilocybin, which is simply the 4-phosphoryl ester of psilocin; psilocybin is converted to psilocin in the body and it is psilocin that is thought to be the active form of psilocybin. This completes the list of naturally occurring psychoactive tryptamine derivatives; two other classes of psychoactive indole compounds, however, are closely related to tryptamine derivatives and deserve to be mentioned here. One of these is the β -carbolines, which, like tryptamines, are structurally simple and widely distributed in the plant kingdom. β -carbolines have a tricyclic structure, with the tryptamine side chain incorporated into a third heterocyclic ring, while tryptamine derivatives have only two fused rings that comprise the indole nucleus. β -carbolines are derived biosynthetically from tryptamine or other simple tryptamines and often are present in the same plants that contain hallucinogenic tryptamines. β -carbolines can be important for the pharmacology of tryptamines, as will be discussed below. Lysergic acid derivatives are another class of naturally occurring psychoactive indoles that can be regarded, in some sense, as complex tryptamine derivatives. The extraordinarily potent hallucinogen LSD is a semisynthetic member of this class, but does not itself occur in nature. Other, less potent but definitely psychoactive lysergic acid derivatives are found in plants, notably the sacred morning glories of Mexico and Central America (members of the genera *Ipomoea*, *Rivea*, and *Turbina*) as well as in the well-known ergot fungus (*Claviceps purpurea* and other *Claviceps* spp.). Other than ergot fungi and the morning glory family (Convolvulaceae), however, lysergic acid derivatives are rare in nature and will not be discussed here further, since they do not strictly conform to the definition of simple tryptamine derivatives, that is, they are not indolealkylamines (Schultes and Hofmann 1981).

The simple hallucinogenic tryptamine derivatives, by which is meant here DMT and its derivatives (5-MeO-DMT, psilocin, psilocybin, and bufotenine), are widely

distributed in nature, occurring in animals as well as plants and fungi (Smith 1977). Tryptamine derivatives have been reported from over 26 higher plant families; the families containing hallucinogenic tryptamine derivatives include the Aizoaceae, Apocynaceae, Poaceae, Fabaceae, Malpighiaceae, Myristicaceae, Pandanaceae, Rubiaceae, Rutaceae, and Urticaceae. Not all of the genera in which these compounds occur are used in shamanic traditions; in fact, it may be argued that the majority of them are not, since their hallucinogenic components were comparatively recent discoveries of modern science, and they were either overlooked or rejected by aboriginal psychopharmacologists. In fact, based on the known numbers of species in each genus reported to contain psychoactive tryptamines, these compounds are potentially present in over 4860 higher plant species! Since DMT is only two biosynthetic steps from tryptophan, these numbers are probably a serious underestimate. Psilocybin and psilocin are apparently restricted to higher fungi and are found primarily in mushrooms of the genera *Psilocybe*, *Stropharia*, and *Panaeolus*, although they have also been reported from other genera of basidiomycetes as well. These compounds have not been reported from any higher plant, although from a biosynthetic standpoint there is no a priori reason why they could not occur in a higher plant. Bufotenine and other tryptamine derivatives are principle constituents of the parotid gland secretions of New World toads belonging to the genus *Bufo*, for which the compound was named when first isolated. Curiously, neither DMT nor 5-MeO-DMT has been reported from any *Bufo* species, with a single exception: *Bufo alvarius*, which contains 5-MeO-DMT; rather staggering concentrations of up to 10% dry weight of the parotid gland have been reported by some investigators (Daly and Witkop 1971; Weil and Davis 1994).

The hallucinogenic tryptamines also display a unique pharmacology that bears importantly on their methods of utilization in the context of New World shamanic traditions. DMT and 5-MeO-DMT are both potent, extremely short-acting hallucinogens whose total duration of action is less than thirty minutes from “baseline” to “baseline.” Neither of these derivatives is orally active, due to degradation by the enzyme monoamine oxidase (MAO), which is present in the liver and gut, as well as in the brain, of humans and other mammals. Thus, in order to experience the hallucinogenic effects of these compounds, they must be taken parenterally as a snuff or enema (although synthetic DMT can also be injected or smoked). If orally ingested, they must be protected from peripheral degradation by a monoamine oxidase inhibitor (MAOI). Traditional shamanic practitioners have ingeniously employed all three of these strategies. In contrast, psilocin, the active tryptamine in the “magic” mushrooms, is orally active and elicits an intense psychedelic experience lasting four to six hours. Psilocin is orally active by itself and does not require an MAOI for activation; as a result, no special preparation is required to experience the effects of hallucinogenic mushrooms. They are quite active when collected and eaten fresh, although they are often dried or stored in honey; these practices are a means of preservation, rather than a specific attempt to alter or activate the pharmacology. Psilocybin is readily converted to psilocin in the body and is considered to be a “pro-drug,” i.e., the physiologically active form is psilocin.

1.3 Survey of New World Tryptamine Hallucinogens

1.3.1 Psilocybe Mushrooms

Just as DMT can be regarded, in some respects, as the prototype hallucinogen, the so-called magic mushrooms of Mexico qualify as the prototype of the New World hallucinogens. The Spanish conquistadores encountered a flourishing mycolatrous religion among the Aztecs at the time of the arrival of Cortés in the court of Moctezuma in 1519. Wasson (1980) has adduced evidence that the use of the magic mushrooms was spread throughout Mesoamerica at this time, and in some parts of the region, the practice may have dated well before the Christian era. Based on linguistic analyses of lexicons compiled by the Spanish missionaries, Wasson has presented convincing evidence that the inebriating mushrooms were known, not only to the Aztecs and Maya, but also to the Nahua, Otomi, Matlatzinca, Mazahua, Tarascan, Huastecan, Totomac, Mixe, Zoque, Mazatec, Zapotec, Chatino, Mixtec, and Chinantla linguistic groups. The discovery of “mushroom stones,” carved effigies in the shape of mushrooms from the highlands of Guatemala, lends additional credence to his arguments. Some of these have been dated to the sixth century BC, indicating the considerable antiquity of the Mesoamerican mycolatry (Borhegyi 1961).

The Spanish missionaries, following close upon the coattails of Cortés, regarded the Aztec’s ritual and religious use of *teonanácatl*, a name erroneously translated as “god’s flesh” by one of their number, one Motolinía, as a particularly odious and blasphemous parody of the Christian Eucharist. They lost no time in pursuing the vigorous suppression of *teonanácatl* in all of its diabolical manifestations and, backed by the considerable intimidatory powers of the Spanish Inquisition, succeeded in driving the practice underground for the next 400 years (Wasson 1980). Despite the most energetic efforts to stamp out the use of the inebriating mushrooms in Mesoamerica, their employment in a religious and ritual context persisted into the twentieth century, when it was rediscovered and made known to the world by the famous team of R. Gordon and Valentina Wasson, in an article published in *Life* magazine in May, 1957 (Wasson and Wasson 1957). The repercussions of that event are still being felt, as this was really the first representation in popular media that such peculiar agents as psychedelic drugs even existed (LSD and peyote had been known for some decades but were familiar only to a few psychiatrists and literati). The Swiss chemist Albert Hofmann, the discoverer of LSD, shortly succeeded in isolating and characterizing the active principles of the magic mushrooms, psilocybin and psilocin, from material Wasson had brought to him from Mexico, thus marking yet another milestone in the history of psychedelic psychopharmacology (Heim and Hofmann 1958). In the early 1960s, the availability of these compounds from Sandoz for research purposes piqued the curiosity of one young Harvard psychologist, Dr. Timothy Leary, and the revelations he gained after a number of self-experiments with these novel substances led him to found the psychedelic movement that would shortly sweep North America and the world. Thus, it happened that a persecuted and reviled substance that had been at the heart

of Mesoamerican religion since prehistoric times began a second career in the twentieth century. The possible clinical uses of psychedelics are only now being rediscovered after a hiatus of some forty years following their blanket prohibition in 1970. Of the many compounds that show promise for therapeutic use, psilocybin is one of the most promising; its lack of toxicity, short duration of action, and profound yet manageable psychedelic effects make it ideal for use in clinical settings.

The magic mushrooms encountered and collected by Wasson and his colleague, French mycologist Roger Heim, comprised about a dozen members of the genera *Psilocybe*, *Panaeolus*, and *Stropharia*, and were for the most part strict endemics, native only to the highlands of Central America. Subsequent work by ethnomycologists has shown that other species of psilocybin-containing mushrooms have a cosmopolitan and global distribution; in the tropics, this is exemplified by *Psilocybe cubensis* (formerly classified as *Stropharia cubensis*, one of the species collected by Wasson and Heim), while in temperate regions, the diminutive “Liberty Cap” mushroom, *Psilocybe semilanceata*, can be found in grassy meadows throughout North America and Europe. Guzmán et al. (2000) published a comprehensive list of the 186 known psilocybin-containing species in an Italian journal; the list can be found on the Erowid.org database (Erowid.org 2001a, b). The majority of the known species belong to the genus *Psilocybe*, but other genera reported to contain psilocybin include *Agrocybe*, *Conocybe*, *Copelandia*, *Panaeolina*, *Panaeolus*, *Galerina*, *Gymnopilus*, *Inocybe*, *Pluteus*, *Hypholoma*, *Gerronema*, and *Mycena*. Besides Mexico and Central America, another part of the New World that is particularly rich in psilocybin species is the Pacific Northwest of North America, where over 30 species are endemic. Curiously, although the recreational use of some of these species has become a popular pastime in recent years, there is no record that these mushrooms or their properties were known to any of the aboriginal groups who inhabited the Northwest Coast. These groups, including the Haida, Tlingit, Tsimshian, and Salish, have never admitted knowledge of these species to ethnographers, although they possess a strong shamanic tradition and much of their traditional art could be characterized as “visionary” in nature. There is similarly no definitive evidence that psilocybin mushrooms had a place in shamanic practices in South America, although Schultes and Hofmann (2001) speculate that seventeenth-century reports by Jesuit missionaries referring to the use of a “tree fungus” for preparation of an intoxicating beverage by the Yurimaguas of the Peruvian Amazon may have referred to *Psilocybe yugensis*, a wood-growing species. In the same volume, they also mention the so-called telephone bell gods, anthropomorphic gold pectorals with dome-shaped ornaments on the head. These artifacts are reported from the Sinú region of northern Colombia and from the Calima region on the Pacific coast. The hemispherical ornaments, complete with a stem or stipe, are strongly suggestive of a mushroom effigy. Similar artifacts have been reported from Panama, Costa Rica, and Yucatan, suggesting that the prehistoric Mesoamerican mushroom cults may have extended as far south as modern-day Colombia. In any case, there is no evidence for contemporary use of psilocybin mushrooms in indigenous shamanic practices in South America.

1.3.2 *Anadenanthera* Snuffs

Now let us shift our focus southward, to the tryptamine-based hallucinogens that are endemic to the South American continent, for it is here that such plants and the sophisticated technologies used in employing them reached their fullest expression.

Among the many medicinal plants that Columbus encountered in his earliest visits to the New World, the intoxicating snuff prepared from the seeds of the Fabaceous tree *Anadenanthera peregrina* (formerly *Piptadenia peregrina*) may be considered the paradigm of hallucinogenic New World snuffs. While presumably Columbus observed the use of the snuff powder on his initial voyage, it was not until his second landing in the New World that he commissioned Friar Ramón Pané to undertake an ethnographic documentation of the use of *cohoba* (or *cogioba*), as it was known to the Taino people, the indigenous inhabitants of what is now Haiti and the Dominican Republic:

The cogioba is a certain powder which they take sometimes to purge themselves, and for other effects which you will hear of later. They take it with a cane about a foot long and put one end in the nose and the other in the powder, and in this manner they draw it into themselves through the nose and this purges them thoroughly... [the *bohuti*, physician] takes a certain powder called *cohoba* snuffing it up his nose which intoxicates them so that they do not know what they do and in this condition they speak many things incoherently in which they say they are talking with the *cemis* and that by them they are informed how the sickness came upon them... (Wassén 1964).

Some scholars have asserted that the Taino word *cohoba* stood for tobacco, but Wassén cites evidence that the words *cohoba*, *cohobha*, *cahoba*, *cojoba-cogioba*, *cojioba*, *cohiba*, and *coiba* are equivalent and refer to a plant that was used by the medicine men to induce a state of trance, and that this was recognized as distinct from tobacco by the early chroniclers. To confuse matters further, the powdered *Anadenanthera* seeds may have been mixed with tobacco, at least on some occasions; the Jirara and Caquetio tribes of Venezuela, considered closely related to the West Indian Taino, commonly employ a mixture of tobacco and *Anadenanthera* snuff. The practice is also widespread among other snuff-using South American tribes (Wassén 1967).

Possibly as a result of this confusion of the two plants by the explorers in Columbus' party, as well as the rather more spectacular method of smoking tobacco that he observed among the peoples of the Antilles on his first voyage in 1492, Columbus took tobacco seeds back to Europe, but neglected to take seeds of *Anadenanthera*. Tobacco smoking quickly became a popular custom and diffused into Spanish society, and "within a few decades, there were more Spaniards converted to smoking than Indians converted to Christianity" (Emboden 1979). One is tempted to speculate how different our contemporary civilization might be had Columbus returned with the seeds of *cohoba*, rather than tobacco!

More modern ethnographic investigations have shown that the historical use of *cohoba* in the West Indies marks the easternmost boundary of the custom. The *Anadenanthera peregrina* used in that region were probably introduced cultivars from the South American mainland; the center of concentration of the species is the Orinoco valley of Colombia, Venezuela, and adjacent parts of Brazil, where it is

known as *yopo*, or *niopo*. Archeological evidence in the form of carved snuff trays and snuffing tubes has placed the practice as far north as Costa Rica (Wassén 1967).

Further to the south, in the Atacama desert, another snuff, known as *vilca* or *huilca* in Peru and Bolivia and *cébil* in Northern Argentina, was similarly prepared from a different *Anadenanthera* species native to this region, *A. colubrina*. Many well-preserved grave sites containing snuffing implements, including carved snuff trays, snuffing tubes, and woven bags containing snuff powders, have been excavated in this area and dated to as early as 570 AD. A chemical and contextual analysis of the powders and implements recovered from these sites established the presence of tryptamine alkaloids in the snuff powders, thus confirming their identity as derived from *Anadenanthera* species (Torres et al. 1992). This evidence, combined with the archeological documentation of the antiquity of this practice in this region, has raised questions as to the true geographic origins of the practice, since it predates by approximately 1000 years any similar documented use of *Anadenanthera* snuffs in the Orinoco valley or the West Indies. It has been generally assumed among archeologists and ethnographers that the practice originated in the Orinoco valley and from there diffused north to Central America, east to the Antilles, and south to coastal Peru and Chile. This more recent evidence, however, suggests the possibility that the practice may have originated in the Atacama region and diffused north and eastward into the Orinoco basin, where the closely related native species, *A. peregrina*, was substituted for the more endemic southerly species, *A. colubrina*.

The excavation of paraphernalia, specifically snuff trays and snuffing tubes, enables estimation of the antiquity of the use of *Anadenanthera* snuffs. The oldest known snuffing implements have been dated to 1200 BC from an excavation by Junius Bird from the site of Huaca Prieta in the Chicama Valley on the central Peruvian coast (Torres 1995).

The primary indole alkaloid constituents of *Anadenanthera* species have been exhaustively reviewed by Torres and Repke (2006). The most abundant alkaloids reported from *A. peregrina* and *A. colubrina* are bufotenine, DMT, and 5-MeO-DMT. However, trace concentrations of a number of structurally related alkaloids, including *N*-methyltryptamine (NMT), 5-methoxy-*N*-methyltryptamine (5-MeO-NMT) DMT-*N*-oxide, serotonin, *N*-methylserotonin, bufotenine-*N*-oxide, and three β -carboline (2-methyl-tetrahydro- β -carboline, 2-methyl-6-methoxy-tetrahydro- β -carboline, and 1,2-dimethyl-6-methoxy-tetrahydro- β -carboline) have been detected.

1.3.3 *Virola* Snuffs and Pastes

Ethnographers had long assumed that *Anadenanthera* species comprised the sole botanical source of psychotomimetic snuffs in use among indigenous peoples in the Amazon Basin, apart from tobacco snuff and the occasional use of coca as a snuff (Cooper 1949). However, subsequent investigations by ethnobotanist R.E. Schultes and toxicologist Bo Holmstedt in the 1950s and 1960s established that the use of *Anadenanthera* snuffs was less prevalent than formerly thought and that tribes belonging to the Waika groups in the upper Orinoco valley prepare an intoxicating

snuff from the resin (sap) of several species of the genus *Virola*, in the Myristicaceae, or nutmeg family (Schultes and Holmstedt 1968). In addition to the Orinoco valley, the use of *Virola* snuffs is concentrated in the Colombian Vaupés and north of the Rio Negro in Brazil. Some overlap in the native nomenclature has undoubtedly contributed to the confusion regarding the distinction between *Virola* and *Anadenanthera* snuffs. Terms vary in different tribes, but *Virola* snuff is known as *yá-kee*, *yá-to*, and *paricá* in Colombia and Venezuela, and *epéna*, *ebene*, *paricá*, and *nyakwána* in Brasil. However, *paricá* may also refer to *Anadenanthera* snuff, and *epéna*, or *ebene* can be used as a general term for snuff (Schultes 1970a, b).

The principle species implicated in the preparation of hallucinogenic snuffs in the Colombian Amazon are *V. calophylla* and *V. calophylloidea*, while *V. theiodora* and *V. elongata* are the species utilized among the Waika, Paumari, and Taiwanos. There is considerable taxonomic confusion in the genus, however, and *V. theiodora* and *V. elongata* are regarded as equivalent by some taxonomists. *Virola cuspidata* and *V. rufula* have also been reported as snuffs. Occasionally, ashes or powdered leaves of other plants are used as admixtures to the snuffs. Among the Waika, one commonly employed admixture is the aromatic herb, *Justica pectoralis* var. *stenophylla*, which also is occasionally used as the sole ingredient of a snuff. Earlier reports of tryptamines in *Justicia* are apparently erroneous, although the plant does contain umbelliferone and other coumarins (Macrae and Towers 1984a). Interestingly, the resin of *Virola* species among the Waika is also occasionally used in the preparation of an arrow poison that is applied to darts used in hunting small animals. MacRae and Towers (1984b) investigated the possible mechanisms contributing to this activity in animal experiments. They found that, in their assays, extracts containing the tryptamine alkaloids were not highly toxic and did not interfere markedly with locomotion or motor activity. They isolated an alkaloid-free fraction containing lignans, however, and found that this fraction produced a marked inhibition of motor activity and apparent sedation of the test animals. They concluded that the lignans, rather than the tryptamines, were likely the agents responsible for the effectiveness of *Virola* arrow poison.

The reddish, resinous exudate of the inner cambial layer of the *Virola* species used as snuffs contains high concentrations of tryptamine alkaloids, including NMT, 5-MeO-NMT, DMT, and 5-MeO-DMT, of which the latter usually predominates, and often may be the sole constituent. Traces of β -carbolines, including 2-methyl-1,2,3,4-tetrahydro- β -carboline, 6-methoxy-2-methyl-1,2,3,4-tetrahydro- β -carboline, and 6-methoxy-1,2-dimethyl-1,2,3,4-tetrahydro- β -carboline have also been reported in some species (Holmstedt and Lindgren 1967). Both the source plants and the snuffs prepared from them exhibit considerable chemical variation.

In the Colombian Putumayo, marked on the north by the Rio Igaraparaná, and on the south by the Rio Yaguasyacu and Ampiyacu, the Bora, Witoto, and Muinane prepare an orally active hallucinogen from the resin of *Virola theiodora*, *V. elongata*, and *V. pavonis* (Schultes 1969). In this practice, the drug, which is known as *oo-koo-he* among the Witoto and *kú-ru-ku* among the Bora, is prepared by stripping the bark, collecting the resin, and concentrating it to a thick, syrupy consistency. This is then mixed with the ashes of other plants (usually *Gustavia peoppigiana* or *Theobroma* spp.) and rolled into pellets or boluses. Oral ingestion of two or three of

these pellets is said to induce a rapid and violent intoxication, an effect that the author was able to confirm in self-experiments during fieldwork on the Rio Ampiyacu (McKenna et al. 1984a). Since the psychotomimetic tryptamines DMT and 5-MeO-DMT, the major alkaloids in the preparation, are not orally active unless activated by a monoamine oxidase inhibitor (MAOI), the documented oral activity of these *Virola* pellets raises some interesting pharmacological questions. Phytochemical analyses have shown that β -carbolines, while acting as potent MAOI inhibitors, are only present in trace concentrations in the *Virola* pellets and hence are unlikely to have any pharmacological significance. In vitro assay of extracts prepared from the pellets showed a somewhat weak MAOI activity, which moreover was shown to be due to the tryptamines alone; extracts from which the tryptamines were removed did not display any MAOI activity. At present, the pharmacological basis for the oral activity of the *Virola* pellets remains incompletely elucidated (McKenna et al. 1984a).

1.3.4 *Ayahuasca*

The orally active *Virola* pellets always had a restricted ethnographic distribution and the practice is now verging on extinction as a result of encroaching acculturation among the tribes that formerly used it. In contrast, the hallucinogenic beverage known variously as *ayahuasca*, *yagé*, *caapi*, *natema*, or *hoasca*, is the premier hallucinogen of the Amazon, and its use, far from dying out, is rapidly diffusing from aboriginal and mestizo society into mainstream South American (and global) culture. Like the *Virola* pellets, *ayahuasca* is also an orally active tryptamine-based hallucinogen, but its mechanism of action is relatively well understood.

Ayahuasca is prepared by boiling the bark or crushed stems of a Malpigiaceous jungle liana, *Banisteriopsis caapi*, together with various admixture plants, especially the leaves of *Psychotria viridis*, a member of the Rubiaceae. In the Colombian Putamayo and parts of Ecuador, the leaves of *Diplopterys cabrerana* (formerly classified as *Banisteriopsis rusbyana*) (Gates 1979), a liana in the same family as *Banisteriopsis*, are often substituted for those of *Psychotria viridis*. It is the admixture plants, *Psychotria* or *Diplopterys*, that contain the hallucinogenic alkaloid necessary for the activity; the leaves of both species contain substantial concentrations of DMT (Der Marderosian et al. 1968; Pinkley 1969). The *Banisteriopsis* liana, on the other hand, contains high concentrations of β -carboline alkaloids, primarily harmine and tetrahydroharmine, with lesser amounts of harmaline (Rivier and Lindgren 1972; Schultes and Hofmann 1981). These compounds are potent peripheral MAO inhibitors, and it is the combination of DMT in the admixtures and the MAO-inhibiting β -carbolines that provide the mechanism for the oral activity of this drink. The β -carbolines are able to protect the DMT from degradation in the liver and gut, thus enabling it to cross the blood-brain barrier intact and exert its effect in the central nervous system (McKenna et al. 1984b).

Unlike the hallucinogenic snuffs or the *Virola* pellets, the custom of using *ayahuasca* has a widespread distribution among aboriginal groups in the Amazon, including the Guahibo, Jivaro, Colorado, Ingano, Siona, Kofan, Witoto, Tukano, Desana, Yakuna, and more than 20 others. In view of this widespread use, it is not surprising that the practice has diffused into mestizo society; in Peru and parts of Colombia and Ecuador, *ayahuasca* (or *yagé*, as it is known in the Colombian Putamayo) occupies a central position in the ethnomedical armamentarium of mestizo shamans. These practitioners consume the beverage themselves as a diagnostic and divinatory tool and also administer it to their patients as a panacea reliably able to cleanse both the body (it is often referred to as “la purga”) and spirit. Regular consumption of *ayahuasca*, along with a special diet, sexual abstinence, and ingestion of other medicinal plants, also constitutes an essential part of shamanic training for a mestizo healer. Thus, *ayahuasca* is the primary “teacher” enabling the apprentice medicine man to learn about the curative properties of other plants (often by consuming them in the form of admixtures to *ayahuasca*), which are also conceived of as “plant teachers.” (Luna 1984; McKenna et al. 1995). It is also through the medium of *ayahuasca* that the shaman acquires his “icaros,” magical songs that are used in curing, and establishes alliances with his helping spirits, which may be conceived as animals, plants, or spirits (Luna 1984).

The origin of the use of *ayahuasca* by indigenous Amazonian peoples is lost in antiquity, and there is evidence that the practice was already centuries old by the time of the Columbian contact. Unlike snuffs, which leave unambiguous archeological evidence in the form of snuff trays and tubes, *ayahuasca* is consumed as a decoction, and there is no definitive link to ceramic or other vessels that may have been used to consume the beverage. Based on ambiguous evidence, Naranjo (1995) speculates that the earliest use of *ayahuasca* can be placed sometime between 500 BCE and 500 AD.

Whatever its historic context has been, in recent decades the ceremonial use of *ayahuasca* in a religious context has begun to diffuse from mestizo society into a wider cultural milieu. In Brazil, where it is known as *hoasca* or *Daime*, the beverage has become the central sacrament of several syncretic religious movements. The largest and most visible of these is the *Santo Daime* cult, which incorporates many elements of Christian liturgy in their practices and belief systems (Dale 1991) and the *União do Vegetal*, in which a collective spiritualism emphasizing ecology and harmony with nature plays a more prominent role. These cults have burgeoned from a few hundred members to thousands of members within the last two decades. The Brazilian government, recognizing that these are legitimate religious movements and perceiving little or no physical or moral detriment from their use of *ayahuasca*, has officially sanctioned *ayahuasca* by lifting legal restrictions against its sacramental use within a religious context (Erowid.org 2001a, b). In the USA, judicial rulings by the Supreme Court and the US District Court in Oregon have sanctioned the religious use of *ayahuasca* for practicing members of the UDV and Santo Daime churches (Erowid.org 2006; 2012).

1.3.5 *Bufo* Species and *Jurema* (*Mimosa* Species)

All of the New World tryptamine hallucinogens that we have discussed to this point—the psilocybin mushrooms, the *Anadenanthera* snuffs, the *Virola* preparations, and *ayahuasca*—have an extensive history and an association with New World shamanism that is Paleolithic in their origins. Their impact and influence on the cultures that utilized them is abundant and well documented, both in the ethnographic literature and in the art and iconography of the peoples who use the plants.

In the case of two other tryptamine hallucinogens, however, the information on their use in the New World is sparser, and as a result they are all the more fascinating; these are uncharted ethnopharmacological waters.

Bufo Species

It was mentioned above in the section on the distribution of the tryptamines in nature that bufotenine, as its name implies, was first isolated from the venom of toads of the genus *Bufo* and that in at least one instance (*Bufo alvarius*) the potent hallucinogen 5-MeO-DMT was a major ingredient of the venom. While it is true that the toad occupies a prominent position in Mayan, Aztec, and Olmec iconography (Kennedy 1982) and is often depicted together with mushrooms and stylizations of other “sacred” plants, there is no unambiguous proof that toad venom was used as a hallucinogen in Mesoamerica. A major source of controversy has been that the candidate species favored by most ethnographers has involved *Bufo marinus*, which is a highly toxic species that would require a rather sophisticated preparation if it were to be consumed safely. Davis and Weil have extensively reviewed the evidence for the hallucinogenic use of *B. marinus*, and they argue that *Bufo alvarius* is the more likely candidate to have been used, on both pharmacological and ethnographic evidence (Davis and Weil 1992, 1994).

Mimosa Species


Schultes reports that several tribes of eastern Brazil prepared the root of *Mimosa hostilis*, a scrubby, leguminous shrub native to the dry area, into a “miraculous drink” known as *ajuca* or *vinho de jurema*. Early reports of the *jurema* ceremony date back as far as 1788, and the practice is apparently ancient, having been practiced by a number of extinct tribes: Guegue, Acroa, Pimenteira, and Atanayé. A major application of the *jurema* ceremony at one time was apparently to prime the priests and warriors for going off to war (Schultes and Hofmann 1981).

In 1946, Brazilian chemist Oswaldo Gonçalves de Lima isolated a single alkaloid from the roots of a related species, *Mimosa tenuiflora* (*juremapreta*), which he named nigerine. Although this initial isolation was only partially pure, it was subsequently shown to be identical to DMT when Gonçalves de Lima provided a group of American researchers with a sample of *M. tenuiflora* root bark. These

workers were able to unequivocally isolate DMT from the sample in 0.57% yield (Pachter et al. 1959). The history of this significant discovery—the first identification of DMT as a naturally occurring alkaloid—has been exhaustively reviewed by Ott (1998). Although as Ott points out, priority for the first **unequivocal** identification of DMT as a natural compound must be given to Fish et al. (1955) who reported DMT in the seeds of *Anadenanthera peregrina* (under its former name, *Piptadenia peregrina*). DMT is known to be orally inactive unless ingested with an MAOI, and in the traditional psychedelic brew *ayahuasca*, the DMT is protected from peripheral degradation by the β -carboline alkaloids present in the bark of one of the plant components (the liana *Banisteriopsis caapi*). *Vinho de Jurema*, however, is prepared as a beverage without the use of β -carboline containing admixture plants, and it has long been speculated that there must have been some long-forgotten admixture added to enable its oral activity. Ott (1998), however, conducted careful self-experiments using oral decoctions of *M. tenuiflora* (*Juremapreta*) and reported that it was potently psychoactive without the inclusion of any other admixture plants. Although the mechanism of its oral activity remains a mystery, the mystery may have been partially solved by the recent identification of another alkaloid, yuremamine, by J.C. Callaway and co-workers (Vepsäläinen et al. 2005).

Yuremamine, present in the stem bark of *Mimosa tenuiflora* at concentrations comparable to DMT, contains an unusual structure (Fig. 2) that incorporates the

Fig. 2 Structure of Yuremamine



structure of DMT fused with phenolic moieties. The authors suggest that this novel compound may be active as an MAOI, and if confirmed this would account for the oral activity of this unusual preparation. Alternatively, cleavage of the D ring of the yuremamine molecule could free the DMT “caged” in the yuremamine structure. It is possible that the yuremamine is absorbed intact through the gut and the DMT subsequently becomes bioavailable through this mechanism. A third possibility is that yuremamine itself is hallucinogenic and thus accounts for the oral activity of traditional single-plant *jurema* preparations. Resolution of this question must await the isolation of sufficient quantities of pure yuremamine to permit a human bioassay. This interesting and little-known New World hallucinogen is yet another incompletely explored niche of ethnopsychopharmacology, awaiting the time and interest of some devoted investigator.

2 The Neuroscience of Ayahuasca

2.1 *The Nuclear Medicine Approach*

Using single photon emission tomography (SPECT), we conducted a neuroimaging study to assess the acute effects of a high ayahuasca dose in 15 healthy volunteers. We administered a dose of freeze-dried ayahuasca equivalent to 1.0 mg DMT per kg body weight in one experimental session and a placebo in another session. A radiotracer was injected at the peak of the experience, one hour and forty minutes after ayahuasca intake. Subsequently, we obtained brain images showing regional cerebral blood flow at the time of injection (Riba et al. 2006).

As shown in Fig. 3, the statistical comparison between the images obtained after ayahuasca and the images obtained after a placebo revealed changes in a number of brain regions. The changes after ayahuasca were always increases in blood flow, and to our surprise, they were not found in low-level primary visual or auditory areas where we had expected changes based on the well-known effects of the ayahuasca on perception. Instead of effects on these hierarchically low sensory-selective regions, the increases occurred in regions placed higher in the information processing hierarchy, predominantly in anterior brain regions. We located significant clusters of activation in the medial aspects of the frontal lobe in an area encompassing parts of the anterior cingulate and medial frontal gyri. Increases were also observed in the medial temporal lobe (MTL) around the amygdala, hippocampus, and parahippocampal gyrus.

The medial frontal lobe plays a prominent role in cognitive control and in the binding of affective and cognitive processes, while the medial temporal lobe plays a role in emotional arousal and episodic memory. The pattern of activation we observed was in line with the findings by other researchers who had also administered serotonergic psychedelics and used the same nuclear medicine technique or the more advanced positron emission tomography (PET) technique. In 1992,




Fig. 3 Results of the neuroimaging SPECT study. The analysis showed significant areas of increased regional cerebral blood flow during the peak effects of ayahuasca. Significant clusters were located in: **a** the right anterior cingulate/right medial frontal gyrus; **b** the right insula/right inferior frontal gyrus; **c** the left insula/left inferior frontal gyrus; **d** the ventral anterior cingulate/subcallosal gyrus; and **e** the amygdala/parahippocampal gyrus. Results are shown at a p value of $p < 0.002$ uncorrected for an $n = 15$ subjects

Hermle and his team described a hyperfrontality pattern following the administration of mescaline (Hermle et al. 1992). The groups led by Vollenweider and by Gouzoulis-Mayfrank both observed increased fluorodeoxyglucose uptake in the medial prefrontal cortex after the administration of psilocybin (Vollenweider et al. 1997; Gouzoulis-Mayfrank et al. 1999). This converging evidence highlights the frontal cortex with its prominent role in executive function as a key target of psychedelic drugs.

2.2 Spectral Analysis of Brain Electrical Activity

In a previous study involving 18 participants and an ayahuasca dose equivalent to 0.85 mg DMT/kg body weight, we recorded the brain's spontaneous electrical activity (EEG) with sensors placed on the scalp (Riba et al. 2004). The spectral

analysis of ayahuasca-induced changes in the EEG showed reductions in absolute power in all the classical frequency bands of the EEG. We subjected these power changes to intracerebral current density analysis in order to find their brain sources. The results showed only a partial overlap with the findings from the SPECT study. While there were reductions in the MTL and in the medial frontal lobe that matched the SPECT findings, we also found current density reductions in an extensive area in the posterior part of the brain, in the temporo-parieto-occipital junction that includes areas of the parietal, temporal, and occipital lobes. We found the effects specifically over the angular gyrus, the superior parietal lobule, the supramarginal gyrus, the precuneus, and the posterior cingulate cortex. We have replicated these findings more recently in another study involving the administration of two consecutive doses of ayahuasca, as shown in Fig. 4, and they have been independently corroborated by other researchers using magnetoencephalography (Muthukumaraswamy et al. 2013).

It is noteworthy that the brain areas identified using current density analysis correspond predominantly to association areas rather than primary sensory cortex. The temporo-parieto-occipital junction is involved in the secondary processing of visual and auditory information and has been found to play a role in the voluntary generation of visual imagery (Roland and Gulyás 1994). Additional support for a




Fig. 4 Result of the current source density analysis. The figure shows areas of significant current density decreases in the alpha band of the electroencephalogram following two consecutive doses of 0.75 mg DMT/kg ayahuasca. *Blue* indicates significant decreases at $p < 0.05$ corrected as compared to placebo. *Note* The prominent decreases in posterior brain regions

role of these structures in ayahuasca-induced effects is provided by other authors who have postulated that, rather than requiring activation of the striate cortex, visual imagery is based on a more complex phenomenon involving the retrieval from memory of visual information stored in the temporal association cortex (Sakai and Miyashita 1994). An effect of ayahuasca at this level could explain phenomena such as synesthesia between the auditory and visual sensory modalities, given the lack of direct projections interconnecting primary sensory cortices or modality-specific areas (Mesulam 2000).

The targeted areas are characterized by their capacity to act as directories binding distributed components of sensory representations and associations (Mesulam 2000). They are believed to operate as gateways for integrating and accessing diffusely stored information. Increased excitability in these areas which intervene in higher-order processing and integration of information could underlie the complex cognitive modifications reported by users such as novel associations, insights, and revelations. It seems reasonable to assume that direct excitatory actions at these key structures can effectively modify the flow of information between the regions and consequently modify the ongoing mental activity.

2.3 Structural Brain Modifications in Long-Term Users

A recent study conducted in long-term ayahuasca users provides additional support for the involvement of higher-order association cortex in the effects of ayahuasca (Bouso et al., in press). We obtained high-definition structural images of the brains of 22 ayahuasca users and 22 controls matched for age, sex, years of education, and two intelligence measures (verbal and fluid IQ). We then compared cortical thickness in the two groups, and we also tested the participants for neuropsychological performance. The rationale behind this study was that pharmacological studies have shown that psychedelic 5-HT_{2A} agonists, such as DMT, stimulate neurotrophic factors (Gewirtz et al. 2002) and transcription factors (Frankel and Cunningham 2002; González-Maeso et al. 2007) associated with synaptic plasticity. Neurotrophic factors are small proteins that promote the survival and differentiation of neurons during development and influence neuronal plasticity in the adult brain. Transcription factors are proteins that bind to DNA and control gene transcription into RNA. Hence, transcription factors can stimulate or inhibit protein synthesis. By comparing the images of cortical structure, we expected to detect areas of the brain where structural changes such as increased dendritic arborization, enhanced vascularization, and glial cell proliferation might have occurred.

Interestingly, the analysis found differences in cortical thickness (CT) in anterior and posterior brain midline structures, specifically in the anterior and posterior cingulate cortices. Whereas CT had increased in the anterior cingulate cortex (ACC), thinning was observed in the posterior cingulate cortex (PCC) (see Fig. 5).

In the latter region, the degree of thinning was correlated with lifetime ayahuasca intake. Given that the study was cross-sectional rather than longitudinal, we cannot




Fig. 5 Results of the structural analysis of T1 magnetic resonance images. The maps show areas of significant cortical thickness (CT) differences between ayahuasca users and controls displayed onto an inflated cortex. Regions with significantly lower CT in the ayahuasca group are shown in cool colors (*blue-cyan*), and regions with significantly higher CT appear as warm colors (*red-yellow*). Note CT in the posterior cingulate cortex shows an inverse correlation with the personality dimension of Self-transcendence. That is, participants with greater thinning scored higher on this personality trait

establish a causal relationship between the observed modifications and ayahuasca use, although the data indicate that they are closely related. It is of note that the structural changes were observed in the absence of any impairment of neuropsychological task performance. In fact, ayahuasca users performed better than controls in the two-back test (a measure of working memory), the Wisconsin Card Sorting Test (a measure of executive function) and in the task-switching task (a measure of set shifting) (Bouso et al., in press). Increased CT in the ACC, an area involved in attention and cognitive control, could explain the augmented performance in these tasks, a finding previously observed in experienced ayahuasca users (Bouso et al. 2012, 2013).

Another interesting aspect of the cortical thickness study was that changes in the PCC were associated with differences in personality between the two samples. The ayahuasca users scored higher in Self-Transcendence (ST) than controls, and scores showed a negative correlation with cortical thickness in the PCC. ST is a character dimension of the TCI personality questionnaire developed by Cloninger et al. (1993). It measures the individual's degree of religiousness and spirituality.

A possible role for the PCC mediating this facet of personality is of particular interest. The PCC is a key region within the default mode network (DMN), a series of functionally connected structures that have been associated with the intimate sense of self (Cavanna and Trimble 2006). Research in the 1960s showed that psychedelic experiences could be profound and lead to a more spiritual and less materialistic attitude. Our study suggested that these personality changes could have a neural basis and highlighted the involvement of the medial aspects of the frontal and parietal lobes in the (long-term) effects of ayahuasca and potentially in the effect of other psychedelics.

2.4 Functional Connectivity of Brain Oscillations

The structural study discussed above provided evidence of the involvement of both anterior and posterior brain regions in the effects of ayahuasca. In our most recent study, we corroborated this finding, reconciling the seemingly contradictory results of the initial SPECT and electrical source location studies. We assessed how ayahuasca modifies the normal flow of information within the brain during its acute effects. To do so, we studied the coupling of electrical signals using transfer entropy. Transfer entropy is a mathematical measure of functional connectivity based on the information theory that is model-free and takes into account both the linear and nonlinear components of signals. This measure can be applied to electrical brain oscillations; it identifies causal relationships and allows inferences regarding the directionality of information flow. Transfer entropy from y to x measures the amount of uncertainty reduced in the future values of x by taking into account the past values of y , as compared to when only the past values of x are used. Mathematically, this can be expressed as follows:

$$TE_{y \rightarrow x} = \sum_{x_{n+1}} p(x_{n+1}, x_n, y_n) \log \left(\frac{p(x_{n+1}, x_n, y_n) p(x_n)}{p(x_n, y_n) p(x_{n+1}, x_n)} \right)$$

When the time series associated with spontaneous brain electrical activity was analyzed using TE, results showed significant ayahuasca-induced changes in the coupling of signals between anterior and posterior recording sites. Frontal sources decreased their influence over central, parietal, and occipital sites. At the same time, sources in posterior locations increased their influence over signals measured at anterior locations (see Fig. 6). These modifications were maximal at the time point when DMT plasma levels were highest and subjective effects most intense.

These findings indicate that ayahuasca modifies the functional coupling of oscillatory signals along the anterior-to-posterior axis. Given the asymmetric nature of transfer entropy, the results indicate a decrease in the predictability of activity in posterior areas based on the information available at anterior sites. They also indicate an increase in the predictability of activity in anterior areas when




Fig. 6 Results of the transfer entropy (TE) analysis. The first two rows show maps of significant changes in connections between the corresponding electrodes. *Warm colors* indicate significant increases (first row) and *cold colors* (second row) indicate significant decreases. *Thick dark-colored* connections indicate statistically significant changes with p values lower than 0.01, whereas *thick* and *thin light-colored* connections indicate p values lower than 0.05 and 0.1, respectively. The third and fourth rows show the directionality maps depicting the number of outgoing (in green) or incoming (in gray) connections for each electrode. *Note* The decrease in anterior-to-posterior information transfers at 1.5 and 2.5 h, and the increase in posterior-to-anterior information transfers at 2 h

information at posterior sites is taken into account. Thus, the dynamics of the interaction between the higher-order frontal regions and the more sensory-selective posterior areas is modified. These results are in line with the findings in a functional MRI study in which functional connectivity between the frontal and parietal cortices was also found to be reversed by ayahuasca (de Araujo et al. 2012). Thus, under the influence of ayahuasca, the normal hierarchical structure regulating the flow of information is altered. Top-down or feedback control is reduced, and bottom-up or feedforward information is increased. This temporary disruption of normal information processing leads to a change in the “internal dialogue” and the experience of the world, as explained below.


2.5 A Model of Psychedelic Drug Effects on the Human Brain

Using the comprehensive data we have gathered using several techniques, we propose a model of how ayahuasca and, by extension, other serotonergic psychedelics work in the human brain. As shown above, these compounds target association cortex, which is responsible for the secondary processing of sensory information and, more importantly, higher-level areas binding information from different sensory modalities and data stored in memory. As we have seen from the TE analysis, ayahuasca transiently disrupts the hierarchies governing the flow of information during normal consciousness.

Classical models of brain function have focused mainly on the bottom-up or feedforward flow of information from primary sensory areas to the modality-specific association areas and from there to the multimodal association cortex that combines all incoming elements into a meaningful whole. However, more recent views also take into account top-down or feedback projections from hierarchically high to low nodes in the network (see Fig. 7a).

These models propose that top-down control also plays a significant role in the interpretation of sensory information. Thus, the experience of reality would involve feedforward and feedback loops, rendering the interpretation of incoming signals (both external and internal) dependent on previous knowledge and expectations (Friston 2005; Mesulam 2008). In this framework, each level in the hierarchy sends backward projections that modulate incoming information based on pre-established constraints. The whole network would be under the executive control of the frontal cortex.

We propose that the interaction of a psychedelic with this network will reduce top-down constraints and increase excitability in various levels of the hierarchy. In the modified state of awareness induced by ayahuasca, weak endogenous activity, be it sensory or amnesic, will be able to reach higher levels in the hierarchy and become consciously perceptible. This would explain the endogenous visual and auditory phenomena reported for psychedelics and the distortion of external stimuli. Even in the absence of strong external sensory input (eyes closed), visions will emerge due to increased activity in brain areas processing visual information. The higher excitability in multimodal brain areas such as the posterior association cortex, the cingulate, and the MTL (Riba et al. 2004, 2006) would explain the rapidly evolving modifications of thought content and the novel associations that stand as characteristic features of the psychedelic experience. Mismatch signals or “discrepancies” with predictions will be sent upstream and a constant updating of these predictions will be necessary in the brain’s attempt to “make sense” of the experience. The novelty and spontaneity of the thought associations occurring, the facilitation of insight, and the new perspective gained into a given matter are dramatic effects of psychedelics. These sensations of novelty and deep meaning are sometimes so compelling that they are experienced as revelations. See, for example, the compilations by Metzner (1999), McKenna (2000).



◀**Fig. 7** Model of ayahuasca and other psychedelics on the human brain. **a** Bottom-up progress of external sensory information from sensory-specific primary cortex to secondary association and multimodal cortex under physiological conditions. Top-down constraints send inferences to lower-order nodes regarding the nature of the incoming information. Depending on the match or mismatch with the inference, an upward error message is sent and an updated prediction generated. The whole inference-prediction error is governed by executive control mechanisms at the frontal cortex. Adapted from Mesulam (2008). **b** Under ayahuasca and other psychedelics, secondary association and multimodal cortex shows enhanced excitability. The nature of information traveling up the hierarchy does not fit top-down predictions and an error message (discrepancy) is sent upwards. New updated predictions need to be generated. Iterations can be maintained even in the absence of incoming external information. A decrease in overall executive control exerted by the frontal cortex leads to a breakdown of “constancies” and a modification of internal dialogue. Elements of information can be associated in unusual ways and new “meaning” ascribed to sensory inputs and internal thoughts. The subjective state generated by the psychedelic is characterized by its novelty and sometimes by its overwhelming nature

Individual differences such as personality, mood, and prior experience with psychedelics will be part of each person’s pre-established constraints and will consequently modulate the experience. The degree to which each person lets go of the cognitive grip exerted by frontal executive control will also influence the experience and could explain the common lack of effects reported by users when ayahuasca is taken for the first time. Directing attention to external cues such as the ritual and other participants or the desire to remain “in control” frequently leads to experiencing very weak effects or none at all. Typically, in subsequent sessions, the participant lets go and strong effects are finally experienced.

2.6 Concluding Remarks

The use of nuclear medicine and neurophysiological techniques has allowed us to identify brain structures targeted by ayahuasca and the changes in neural dynamics underlying the cognitive effects induced by the drug. By acting on key nodes of the association cortex, ayahuasca modifies the flow of information through the brain. The temporary modification of neural hierarchies induces dramatic changes in cognition. The capacity to provide a new outlook on internal and external reality constitutes the uniqueness of ayahuasca and other psychedelics and distinguishes them from all other psychotropic drugs.

References

- Borhegyi SF (1961) Miniature mushroom stones from Guatemala. *Am Antiq* 26:498–504
 Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JA, Hallak JEC, de Araujo DB, Riba J (in press) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. *Eur Neuropsychopharmacol*

- Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, Alcázar-Córcoles MÁ, Araújo WS, Barbanoj MJ, Fábregas JM, Riba J (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. *PLoS ONE* 7:e42421
- Bouso JC, Fábregas JM, Antonijean RM, Rodríguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. *Psychopharmacology* 230:415–424
- Cavanna AE, Trimble MR (2006) The precuneus: a review of its functional anatomy and behavioural correlates. *Brain* 129:564–583
- Cinq-Mars J, Morlan RE (1999) Bluefish caves and old crow basin: a new rapport. In: Bonnicksen R, and Turmire KL (eds) *Ice age peoples of North America*, Corvallis: Oregon State University Press for the Center for the Study of the First Americans, pp. 200–212
- Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. *Arch Gen Psychiatry* 50:975–990
- Cooper JM (1949) Stimulants and narcotics. In: *Handbook of South American Indians*, vol 5. Bureau of American Ethnology Bulletin #143. Smithsonian Institution, Washington
- Dale GD (1991) The Santo Daime Doctrine: an interview with Alex Polari de Alverga. *Shaman's Drum* 22:30–41
- Daly JW, Witkop B (1971) Chemistry and pharmacology of frog venoms. In: Bücherl W, Buckley EE (eds) *Venomous animals and their venoms*, vol 2. Academic Press
- Davis W, Weil AT (1992) Identity of a new world psychoactive toad. *Ancient Mesoamerica* 3:51–59
- Davis W, Weil AT (1994) *Bufo alvarius*: a potent hallucinogen of animal origin. *J Ethnopharmacol* 41:1–8
- De Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, de Martinis BS, Crippa JA, Hallak JEC, Santos AC (2012) Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion. *Hum Brain Mapp* 33:2550–2560
- Der Marderosian AH, Pinkley HV, Dobbins MF (1968) Native use and occurrence of N, N-dimethyltryptamine in the leaves of *Banisteriopsis rusbyana*. *Am J Pharm* 140:137–147
- Emboden W (1979) *Narcotic plants*. Collier Books, New York
- Erowid.org (2001a) A list of the (186) known psilocybin mushrooms. https://www.erowid.org/plants/mushrooms/mushrooms_info12.shtml. Accessed 27 Dec 2014
- Erowid.org (2001b) Legal status of ayahuasca in Brazil. http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law6.shtml. Accessed 29 Dec 2014
- Erowid.org (2006) UDV wins Supreme Court decision on preliminary injunction. http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law22.shtml. Accessed 29 Dec 2014
- Erowid.org (2012) Santo Daime wins court decision. http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law24.shtml. Accessed 29 Dec 2014
- Fish MS, Johnson NM, Horning EC (1955) *Piptadenia* alkaloids—indole bases of *Piptadenia peregrina* (L.) Benth and related species. *J Am Chem Soc* 77:5892–5895
- Frankel PS, Cunningham KA (2002) The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. *Brain Res* 958:251–260
- Friston K (2005) A theory of cortical responses. *Philos Trans R Soc Lond B Biol Sci* 360:815–836
- Gates B (1979) New names in *Banisteriopsis* and *Diplopterys* (Malpighiaceae) of the Guayana highland. *Brittonia* 31:108–109
- Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ (2002) Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. *Pharmacol Biochem Behav* 73:317–326
- González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT (2A) receptor-mediated signaling pathways to affect behavior. *Neuron* 53:439–452

- Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Büll U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol* 20:565–581
- Guzmán G, Allen JW, Gartz J (2000) A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. *Annali dei Musei civici - Rovereto, Italia* 14:189–280 (in English)
- Heim R, Hofmann A (1958) Isolement de la Psilocybine à partir du *Stropharia cubensis* Earle et d'autres espèces de champignons hallucinogènes mexicains appartenant au genre *Psilocybe*. Extrait des Comptes rendus des séances de l'Académie des Sciences, t 247:557–561
- Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. *Biol Psychiatry* 32:976–991
- Holmstedt B, Lindgren JE (1967) Chemical constituents and pharmacology of South American snuffs. In: Efron DH, Holmstedt B, Kline NS (eds) *Ethnopharmacologic search for psychoactive drugs*, US Public Health Service Publication #1645. US Government Printing Office
- Kennedy AB (1982) *Ecce Bufo*: the toad in nature and in Olmec iconography. *Curr Anthropol* 23:273–290
- Luna LE (1984) The concept of plants as teachers among four mestizo shamans of Iquitos, northeastern Peru. *J Ethnopharmacol* 11:135–156
- Macrae WD, Towers GH (1984a) *Justicia pectoralis*: a study of the basis for its use as a hallucinogenic snuff ingredient. *J Ethnopharmacol* 12:93–111
- Macrae WD, Towers GH (1984b) An ethnopharmacological examination of *Virola elongata* bark: a South American arrow poison. *J Ethnopharmacol* 12:75–92
- McKenna DJ (2000) An unusual experience with “hoasca”: a lesson from the teacher. In: Ayahuasca Reader: encounters with the Amazon's sacred vine. Synergetic Press, Santa Fe, pp 154–157
- McKenna DJ, Towers GH, Abbott FS (1984a) Monoamine oxidase inhibitors in South American hallucinogenic plants part II: constituents of orally active Myristicaceous hallucinogens. *J Ethnopharmacol* 12:179–211
- McKenna DJ, Towers GH, Abbott FS (1984b) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β -carboline constituents of ayahuasca. *J Ethnopharmacol* 10:195–223
- McKenna DJ, Luna LE, Towers GH (1995) Biodynamic constituents in *ayahuasca* admixture plants: an uninvestigated folk pharmacopoeia. In: von Reis S, Schultes RE (eds) *Ethnobotany: evolution of a discipline*. Dioscorides Press, Portland
- Mesulam MM (2000) Behavioral neuroanatomy: large-scale networks, association cortex, frontal syndromes, the limbic system, and hemispheric specializations. In: Mesulam MM (ed) *Principles of behavioral and cognitive neurology*. Oxford University Press, New York, pp 1–120
- Mesulam M (2008) Representation, inference, and transcendent encoding in neurocognitive networks of the human brain. *Ann Neurol* 64:367–378
- Metzner R (1999) *Ayahuasca: hallucinogens, consciousness and the spirit of nature*. Thunder's Mouth Press, New York
- Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Erritzoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ (2013) Broadband cortical desynchronization underlies the human psychedelic state. *J Neurosci* 33:15171–15183
- Naranjo P (1995) Archeology and psychoactive plants. In: von Reis S, Schultes RE (eds) *Ethnobotany: evolution of a discipline*. Dioscorides Press, Portland

- Ott J (1998) Pharmahuasca, anahuasca, *vinho de Jurema*: human pharmacology of oral DMT + harmine. In: Müller-Ebeling C (ed) Special: psychoactivity. Yearbook for ethnomedicine and the study of consciousness, 6/7 (1997–1998). Berlin, VWB
- Ott J (2001) Pharmaño-po-psychnautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. *J Psychoactive Drugs* 33:273–281
- Pachter IJ, Zacharius DE, Ribeiro O (1959) Indole alkaloids of *Acer saccharinum* (the silver maple), *Dictyloma incanescens*, *Piptadenia colubrina*, and *Mimosa hostilis*. *J Org Chem* 24:1285–1287
- Pinkley HV (1969) Plant admixtures to *ayahuasca*, the South American hallucinogenic drink. *Lloydia* 32:305–314
- Riba J, Anderer P, Jané F, Saletu B, Barbanoj MJ (2004) Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. *Neuropsychobiology* 50:89–101
- Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. *Psychopharmacology* 186:93–98
- Rivier L, Lindgren J (1972) *Ayahuasca*, the South American hallucinogenic drink: ethnobotanical and chemical investigations. *Econ Bot* 29:101–129
- Roland PE, Gulyás B (1994) Visual imagery and visual representation. *Trends Neurosci* 17:281–287; discussion 294–297
- Sakai K, Miyashita Y (1994) Visual imagery: an interaction between memory retrieval and focal attention. *Trends Neurosci* 17:287–289
- Schultes RE (1969) *Virola* as an orally administered hallucinogen. *Harvard Bot Mus Leaflets* 22:229–240
- Schultes RE (1970a) The New World Indians and their hallucinogenic plants. *Morris Arboretum Bull* 21:3–14
- Schultes RE (1970b) The plant kingdom and hallucinogens (part III). *Bull Narc* 22:25–53
- Schultes RE, Hofmann A (1981) The botany and chemistry of hallucinogens, 2nd edn. Charles C. Thomas Publishers, Springfield, Illinois
- Schultes RE, Hofmann A (2001) Plants of the gods: their sacred, healing, and hallucinogenic powers. Healing Arts Press
- Schultes RE, Holmstedt B (1968) The vegetal ingredients of the Myristicaceous snuffs of the Northwest Amazon. *Rhodora* 70:113–160
- Smith TA (1977) Tryptamine and related compounds in plants. *Phytochemistry* 16:171–175
- Torres CM (1995) Archeological evidence for the antiquity of psychoactive plant use in the central Andes. *Ann Mus Civ Reverero* 11:291–326
- Torres CM, Repke DB (2006) *Anadenanthera*: visionary plant of ancient South America. Routledge, London
- Torres CM, Repke DB, Chan K, McKenna D, Llagostera A, Schultes RE (1992) Botanical, chemical, and contextual analysis of archaeological snuff powders from San Pedro de Atacama, Northern Chile. *Curr Anthropol* 32:640–649
- Vepsäläinen JJ, Auriola S, Tukiainen M, Ropponen N, Callaway JC (2005) Isolation and characterization of yuremamine, a new phytoindole. *Planta Med* 71:1053–1057
- Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. *Neuropsychopharmacology* 16:357–372
- Wassén SH (1964) Some general viewpoints in the study of native drugs especially from the West Indies and South America. *Ethnos* 1–2:97–120
- Wassén SH (1967) Anthropological survey of the use of South American snuffs. In: Efron DH, Holmstedt B, Kline NS (eds) *Ethnopharmacologic search for psychoactive drugs*, US Public Health Service Publication #1645. US Government Printing Office
- Wasson RG (1968) *Soma: divine mushroom of immortality*. Harcourt, Brace, Jovanovich

Wasson RG (1980) *The wondrous mushroom: mycolatry in Mesoamerica*. McGraw-Hill Book Company, New York

Wasson RG, Wasson V (1957) Seeking the magic mushroom. *Life Magazine*, 13 May 1957

Weil AT, Davis W (1994) *Bufo alvarius*: a potent hallucinogen of animal origin. *J Ethnopharmacol* 41(1-2):1-8